Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
02 janv. 2019 08h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Announces Third Quarter 2018 Results and Update
07 nov. 2018 16h01 HE
|
Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
31 oct. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Announces Second Quarter 2018 Results and Update
06 août 2018 16h05 HE
|
Editas Medicine, Inc.
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...
Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
30 juil. 2018 16h02 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
Editas Medicine to Participate in The JMP Securities Life Sciences Conference
13 juin 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor...
Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
08 mai 2018 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of...
Editas Medicine Announces First Quarter 2018 Results and Update
03 mai 2018 16h01 HE
|
Editas Medicine, Inc.
Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield, Ph.D. Cash, cash equivalents, and...
Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
26 avr. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
06 mars 2018 16h01 HE
|
Editas Medicine, Inc.
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22...